November 2014 | OncologyLive

A New Star on Horizon

November 21, 2014

Since the modern era of anticancer immunotherapy began about four years ago, a variety of strategies to awaken the patient's own defenses against tumor cells have been reported.

Outliers Join the Research Fold: Technological Advances Spark Initiatives to Study Exceptional Responders

November 20, 2014

Despite numerous reports of "miracle cures" for a select few patients treated with a variety of different anticancer therapies, drugs that failed to show improvement for a large number of patients have historically been considered failures and have been shelved.

Experts Emphasize Therapy Options, Expanded Mutation Testing in mCRC

November 18, 2014

Confusion persists about the best choice of frontline therapy for patients with metastatic colorectal cancer (mCRC) after a landmark clinical trial that was conceived a decade ago to answer that question concluded without a superiority finding

Novel Radiotherapy Techniques Expand Options for Breast Cancer Patients

November 12, 2014

Those of us who have treated patients with breast cancer for any extended period of time can likely share anecdotes about watching the treatment of this disease evolve to levels many of us could only have imagined when we began practicing.

New Geriatric Assessment Tools Enhance Care of Older Adults with Cancer

November 10, 2014

Amid a coming storm of demographic trends signaling a sharp increase in the number of older people diagnosed with cancer in the United States, researchers are developing new geriatric assessment tools to help oncology specialists better manage this patient population.

Molecular Insights: Tumor Analysis Providing Answers to Clinically Relevant Biological Questions

October 29, 2014

It is increasingly recognized that the era of treating individual advanced or metastatic cancers based essentially on the anatomic site of origin or histologic subtype as determined by light microscopic evaluation is rapidly coming to a close.

Expert Says pCR Data Support Neoadjuvant Therapy in HER2-Positive Breast Cancer

October 22, 2014

Substantial clinical trial evidence supports the use of pathologic complete response (pCR) as a measure for evaluating neoadjuvant therapies for patients with HER2-positive breast cancer, suggesting that preoperative treatment should be the standard of care

Many Companies Join Race to Create Novel CTC Technology

October 16, 2014

At least 30 companies are seeking to develop the next generation of circulating tumor cell (CTC) technology, part of an emerging focus on analyzing the biofluids of patients with cancer as a "liquid biopsy," particularly for solid tumors.